Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Dr. Kate Goodrich, current Chief Medical Officer of Humana, to its Board of Directors. Dr. Goodrich brings over two decades of experience in healthcare innovation and value-based initiatives. As Humana's CMO, she leads clinical operations, healthcare research, and health equity initiatives. Previously, she served as CMO at the Centers for Medicare and Medicaid Services (CMS), where she directed the Center for Clinical Standards and Quality. Dr. Goodrich continues her role as a practicing hospitalist and professor at George Washington University Medical Center while serving on multiple healthcare boards.
Tarsus Pharmaceuticals (NASDAQ: TARS) ha nominato la dott.ssa Kate Goodrich, attuale Chief Medical Officer di Humana, nel suo Consiglio di Amministrazione. La dott.ssa Goodrich porta con sé oltre vent'anni di esperienza nell'innovazione sanitaria e nelle iniziative basate sul valore. In qualità di CMO di Humana, guida le operazioni cliniche, la ricerca in sanità e le iniziative per l'equità sanitaria. In precedenza, ha ricoperto il ruolo di CMO nei Centri per Medicare e Medicaid Services (CMS), dove ha diretto il Centro per gli Standard Clinici e la Qualità. La dott.ssa Goodrich continua a esercitare come ospedaliera e come professoressa al George Washington University Medical Center, mentre partecipa a diversi consigli di amministrazione nel settore sanitario.
Tarsus Pharmaceuticals (NASDAQ: TARS) ha nombrado a la Dra. Kate Goodrich, actual directora médica de Humana, en su Junta Directiva. La Dra. Goodrich aporta más de dos décadas de experiencia en innovación en salud e iniciativas basadas en el valor. Como CMO de Humana, lidera las operaciones clínicas, la investigación en salud y las iniciativas de equidad en salud. Anteriormente, se desempeñó como CMO en los Centros de Servicios de Medicare y Medicaid (CMS), donde dirigió el Centro de Normas Clínicas y Calidad. La Dra. Goodrich continúa su función como médico hospitalario y profesora en el Centro Médico de la Universidad George Washington, al tiempo que participa en múltiples juntas de salud.
타르수스 제약 (NASDAQ: TARS)는 현재 후마나의 최고 의학 책임자인 케이트 굿리치 박사를 이사회에 임명했습니다. 굿리치 박사는 의료 혁신 및 가치 기반 이니셔티브에서 20년 이상의 경험을 가지고 있습니다. 후마나의 CMO로서 그녀는 임상 운영, 의료 연구 및 건강 형평성 이니셔티브를 이끌고 있습니다. 이전에는 메디케어 및 메디케이드 서비스 센터(CMS)에서 CMO로 재직하며 임상 기준 및 품질 센터를 지휘했습니다. 굿리치 박사는 조지워싱턴 대학교 의료 센터에서 병원 의사 및 교수로서 계속 활동하며 여러 의료 위원회에도 참여하고 있습니다.
Tarsus Pharmaceuticals (NASDAQ: TARS) a nommé Dr. Kate Goodrich, actuelle directrice médicale de Humana, à son conseil d'administration. Dr. Goodrich apporte plus de deux décennies d'expérience dans l'innovation en santé et les initiatives axées sur la valeur. En tant que CMO de Humana, elle dirige les opérations cliniques, la recherche en santé et les initiatives d'équité en santé. Auparavant, elle a été CMO aux Centres de services Medicare et Medicaid (CMS), où elle a dirigé le Centre des normes cliniques et de la qualité. Dr. Goodrich continue à exercer en tant que praticienne hospitalière et professeure au George Washington University Medical Center, tout en siégeant à plusieurs conseils de santé.
Tarsus Pharmaceuticals (NASDAQ: TARS) hat Dr. Kate Goodrich, die derzeitige Chief Medical Officer von Humana, in seinen Vorstand berufen. Dr. Goodrich bringt über zwei Jahrzehnte Erfahrung in der Gesundheitsinnovation und wertbasierten Initiativen mit. Als CMO von Humana leitet sie die klinischen Abläufe, die Gesundheitsforschung und Initiativen zur Gesundheitsgleichheit. Zuvor war sie CMO bei den Zentren für Medicare und Medicaid-Dienste (CMS), wo sie das Zentrum für klinische Standards und Qualität leitete. Dr. Goodrich übt weiterhin ihre Rolle als praktische Krankenhausärztin und Professorin am George Washington University Medical Center aus und ist Mitglied mehrerer Gesundheitsbehörden.
- Addition of experienced healthcare executive with expertise in value-based care and patient outcomes
- Strategic appointment that could enhance XDEMVY market positioning and future therapy development
- Brings valuable perspective from both government (CMS) and private sector (Humana) healthcare leadership
- None.
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes
IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access, equity and affordability.
“As a former CMO of Medicare and now CMO of a leading health insurance company, Kate has had an indelible impact on how government and private sector entities approach value-based care,” said Bobak Azamian, M.D., Ph.D., CEO and Chairman of Tarsus. “Her passion for ensuring optimal patient outcomes aligns squarely with our mission, and we are thrilled to apply her expertise to expanding the impact of XDEMVY and communicating the value proposition of future therapies.”
“Tarsus has created an entirely new category of disease, brought it to the forefront, and provided a novel solution to potentially millions of patients. That differentiated approach to patient impact is what drew me to Tarsus,” said Dr. Goodrich. “I am honored to have the opportunity to work with such a forward-thinking Board and executive team as we continue building a leadership stake in eye care and work to bring new medicines to patients in need.”
As Chief Medical Officer for Humana, Dr. Goodrich provides executive clinical leadership for the insurance and CenterWell businesses of Humana, and oversees physician engagement, healthcare research, health equity and social impact initiatives. Previously, she was the Senior Vice President for Clinical Analytics and Trend within Humana’s Clinical Solutions organization, where she was accountable for producing the business analytics and rapid learning approach for clinical programs designed to improve outcomes at lower cost.
Prior to joining Humana, Dr. Goodrich was at the Centers for Medicare and Medicaid Services (CMS), where she was the Director of the Center for Clinical Standards and Quality (CCSQ) and CMS’s Chief Medical Officer. The Center is responsible for numerous quality and value-based purchasing programs including the Quality Payment Program, quality improvement programs in all 50 states, development and enforcement of health and safety standards of all facility-based providers across the nation, and coverage decisions for treatments and services for Medicare.
For more than 25 years, Dr. Goodrich has served as a faculty member at the George Washington University Medical Center (GWUMC). She continues to practice clinical medicine as a hospitalist and professor of medicine at GWUMC. Dr. Goodrich currently serves on the boards of the National Quality Forum, the Institute for Accountable Care and the Delaware Valley ACO. She earned her M.D. from the Louisiana State University School of Medicine and her master’s in health services research from Yale University.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Tarsus is studying three investigational medicines in clinical trials. In addition to XDEMVY (lotilaner ophthalmic solution)
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the benefits and value added by the new director; Tarsus’ commercialization plans for and the anticipated benefits of XDEMVY; development and potential of Tarsus’s current and future pipeline; and the quotations of Tarsus’ management and board member. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2023 filed on February 27, 2024 and the most recent Form 10-Q quarterly filing filed with the SEC, which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contacts:
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
Who is the newest Board member appointed to Tarsus Pharmaceuticals (TARS)?
What is Dr. Kate Goodrich's current role before joining Tarsus (TARS) board?
What was Dr. Goodrich's previous position before joining Humana and Tarsus (TARS)?
